Biodel, Inc. is a development stage biopharmaceutical company. It is focused on the development and commercialization of innovative treatments for diabetes. The company develops product candidates by applying its proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. It develops novel forms of insulin and other peptide hormones for use in treating diabetes and its complications, including hyperglycemia, hypoglycemia, cardiovascular complications and weight control. Biodel was founded by Solomon S. Steiner and Erik I. Steiner on December 3, 2003 and is headquartered in Danbury, CT.